Silicone Breast Implants Are Still Available in Europe

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 8
Volume 4
Issue 8

MIAMI BEACH, Fla--The French response to the FDA ban on silicone breast implants was to issue a strong recommendation to plastic surgeons to stop using silicone-gel-filled implants or polyurethane prostheses. Now that stricter manufacturing controls are in place, that recommendation has been canceled, and today silicone implants are available in most European countries, Jean-Yves Petit, MD, said at the 12th Annual International Breast Cancer Conference.

MIAMI BEACH, Fla--The French response to the FDA ban on siliconebreast implants was to issue a strong recommendation to plasticsurgeons to stop using silicone-gel-filled implants or polyurethaneprostheses. Now that stricter manufacturing controls are in place,that recommendation has been canceled, and today silicone implantsare available in most European countries, Jean-Yves Petit, MD,said at the 12th Annual International Breast Cancer Conference.

Dr. Petit, currently with the European Institute of Oncology,Italy, explored the stability of silicone implants over time ina study at the Institut Gustave Roussy. The study involved 14breast reconstruction patients with 17 implants who were havingtheir implants replaced.

These patients had had their implants for more than 10 years andwere worried about silicone leakage, but none had clinical signsand only one had a radiologic sign of rupture.

The study found five cases of leakage and five cases of rupture,but does such deterioration increase a woman's risk of autoimmunedisease or cancer?

Studies show less than 20 cases of scleroderma following implantationamong more than 2 million US women, he said. And in a retrospectiveanalysis of 146 French women with silicone implants, Dr. Petitfound no increased risk of death from breast cancer (relativerisk, .5) or other causes (relative risk, .7).

Recent Videos
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Related Content